Handbook of Cannabis and Related Pathologies

<p>1. The Cannabis Plant: Botanical Aspects <br>2. The biosynthesis of cannabinoids 3. Increasing plant concentrations of THC and implications on health related disorders <br>3. Age as a Predictor of Cannabis Use <br>4. Lifetime cannabis use and cognition in psychosis spectrum disorders <br>5. A Profile of Synthetic Cannabinoid Users <br>6. Dual disorders in cannabis misuse <br>7. Cannabis use and cognitive function <br>8. Cannabis, migration and psychosis onset <br>9. The global epidemiology and disease burden of cannabis use and dependence <br>10. International aspects of cannabis use and misuse – the Australian perspective <br>11. International aspects of cannabis use and misuse: Egypt <br>12. Cannabis Body Packing – A Caribbean Perspective <br>13. Gender differences in cannabis use disorders <br>14. The role of age in the onset and further development of cannabis use disorders <br>15. Effects of Cannabis Use on Neurocognition in Adolescents and Emerging Adults with Psychiatric Comorbidities <br>16. Correlates and consequences of prenatal cannabis exposure (PCE): identifying and characterizing vulnerable maternal populations and determining outcomes for exposed offspring <br>17. Cannabis and clubbing: Relevance of cannabis and polydrug use in the clubbing culture today <br>18. Cannabis and Sexual Behavior <br>19. Friendships and Cannabis Use <br>20. Students’ knowledge of cannabis <br>21. Childhood trauma and cannabis - risk factors in severe mental disorders <br>22. Parent’s Influence on Their Children’s Cannabis Use <br>23. Cannabis Users and Premorbid Intellectual Quotient (IQ) <br>24. Cannabis and traffic accidents <br>25. Drug-related pictures, attentional bias, and cannabis use <br>26. Cannabis use and first-episode psychosis patients (FEP) <br>27. Cannabis, associative memory, fMRI, and the Implicit Association Test <br>28. Stress Response in Cannabis Users and Psychosis <br>29. Motivation in Chronic Cannabis Use <br>30. Cannabis use and its association to mental illness: a focus on mood and anxiety disorders <br>31. Cannabis Use and Well-being <br>32. Craving and cannabis: A potential paradox <br>33. Delta 9-tetrahydrocannabinol and catalepsy-like immobilization <br>34. The interactive nature of cannabis and schizophrenia risk genes <br>35. Neuroimaging findings in Adolescent Cannabis use and Early Phase Psychosis <br>36. Cannabis smoking in adult schizophrenia: A cognitive and functional magnetic resonance imaging perspective <br>37. The long-lasting effects of cannabis use on movement and brain regions that control movement <br>38. Assessment of cannabis acute effects on driving skills: laboratory, simulator and on road studies <br>39. Chronic cannabis use and axonal fibre connectivity <br>40. Microglial activation and cannabis exposure <br>41. Cannabis and psychosis: correlation, causality and consequences <br>42. Cannabis use and cannabis use disorders in bipolar disorder – causes and consequences <br>43. Cannabis use in epilepsy – risks and benefits <br>44. Cannabis, cannabinoids and visceral pain. <br>45. Cannabis and Post-Operative Analgesia <br>46. Chronic cannabis abuse and thyroid function <br>47. Cannabis Hyperemesis Syndrome <br>48. Cannabis and Cannabinoids and the effects on gastrointestinal function: an overview <br>49. Cardiovascular Effects of Cannabis Usage <br>50. Cannabis and Stroke <br>51. Cannabis Smoking and the Lung <br>52. Cannabis and hepatic injury <br>53. Cannabis allergy: more than a bad trip <br>54. Marijuana and Breastfeeding <br>55. Hypocretins/orexins and addiction: role in cannabinoid dependence <br>56. Regulatory role of cannabinoids for skin barrier functions and cutaneous inflammation <br>57. Cannabinoids and the Cannabinoid Receptors: An Overview <br>58. Signalling and Regulation of the Cannabinoid CB1 Receptor <br>59. Allosteric modulation of the Cannabinoid CB1 Receptor <br>60. The polymorphisms of the CB2 cannabinoid receptor <br>61. Chemistry of Cannabinoid Receptor Agonists <br>62. The endocannabinoid system as a target for new antiseizure drugs <br>63. Pharmacological aspects of anandamide and 2-arachidonoyglycerol as bioactive lipids <br>64. Pharmacological aspects of NMDA receptors, mGluR5, and endocannabinoids <br>65. Peripheral CB1 receptors and ghrelin in feeding regulation. Pharmacological implications. <br>66. Pharmacological aspects of novel antiobesity agents related to cannabinoids <br>67. Cannabinoid reward and dependence: Focus on the main psychoactive ingredients of marijuana in preclinical studies <br>68. Peroxisome proliferator activated receptors and cannabinoids VRP suggested Peroxisome proliferator activated receptors (PPARs) and cannabinoids <br>69. The Protein-Protein interactions of CRIP1a and cannabinoid 1 receptor: the molecular mechanism study through an integrated molecular modeling approach <br>70. Synthetic cannabinoids: A summary of selected phenomena with respect to behavioral pharmacology and abuse liability <br>72. The role of 5-HT1A receptor and nausea and vomiting relief by cannabidiol (CBD), cannabidiolic acid (CBDA) and cannabigerol (CBG) <br>73. Genetic and molecular aspects of addiction with tetrahydrocannabinol <br>74. Effects of dlta 9-Tetrahydrocannabinol in human breast cancer <br>75. Δ9-THC and COX-2 Signaling <br>76. Cannabinoids and the addictive effects of nicotine <br>77. Cannabinoid Regulation of Intraocular Pressure: Human and Animal Studies, Cellular and Molecular Targets <br>78. Ocular Delivery of Tetrahydrocannabinol <br>79. The role of g-aminobutyric acid in the interoceptive effects of oral D9-tetrahydrocannabinol in humans <br>80. The role of the delta-9-tetrahydrocannabinol in diabetes mellitus <br>81. Cannabidiol: An Overview of its Antipsychotic Properties <br>82. Cannabidiol for the treatment of epilepsy: an overview of possible mechanisms of action and preclinical and human studies <br>83. Cannabidiol and neuroprotection: evidence from preclinical studies <br>84. Cannabinoids as Potent Inhibitors of Human CYP1 Enzymes <br>85. Nabilone: Pharmacology and Clinical Applications (Suggest: The Synthetic Analogue of delta 9-tetrahydrocannabinol (THC): Nabilone. Pharmacology and Clinical Application) <br>86. Synthetic cannabinoids in dementia <br>87. Synthetic cannabinoid receptor agonists ("Spice") as new recreational psychoactive substances <br>88. Accidents and synthetic cannabinoids in blood of drivers <br>89. Cannabis and synthetic cannabinoids for cancer patients: Multiple palliative indications together with promising laboratory anti-neoplastic effects <br>90. The Use of Medical Marijuana in the Treatment of Psychiatric Disorders <br>91. Beneficial effects of cannabis and related compounds on sleep <br>92. Cannabinoids for the treatment of Gilles de la Tourette syndrome <br>93. Cannabidiol and multiple sclerosis <br>94. Cannabinoids and Effects on Painful Neuropathy <br>95. Cannabis for basal ganglia disorders (Parkinson's disease and Huntington's disease) <br>96. Medical cannabis for the treatment of Inflammatory Bowel Disease <br>97. Cannabidiol for the treatment of drug use disorders <br>98. Cannabinoids and the effects on gastrointestinal tract: a focus on motility <br>99. Potential medical uses of cannabigerol: a brief overview <br>100. The Cannabis Abuse Screening Test (CAST) and applications <br>101. Screening of synthetic cannabinoids <br>102. On-site Drug testing for Cannabis <br>103. Cannabinoids in Oral Fluid: Identification and Interpretation of Analytical Results <br>104. Cannabinoids in exhaled breath <br>105. Barriers to treatment seeking for cannabis dependence <br>106. Pharmacotherapies for cannabis use disorders <br>107. Self-Initiated Cannabis Use Cessation in Adolescents and Emerging Adults <br>108. Treating cannabis dependent adolescents with family therapy <br>109. Cognitive Behavioral Therapy in Cannabis Use Disorder <br>110. Cannabis withdrawal symptoms in cannabis and poly drug users <br>111. School-based cannabis prevention programs <br>112. The CapOpus trial for cannabis use disorders <br>113. Treating cannabis use disorders through technology assisted interventions: the telephone and internet <br>114. Reducing cannabis use with a real-time intervention using mobile technology <br>115. Further information: Cannabis Neuropathology Resources and Recommended Reading</p> <p>Online Only Chapters:<br>1. Tetrahydrocannabinol concentration and genetic characterization of cannabis.<br>2. Cannabis Use in Youth Subcultures<br>3. Aggressive Behavior and Cannabis Use<br>4. COMT genotypes, cannabis use and psychosis: gene-environment interaction evidence from human populations and its methodological concerns<br>5. Neuroimaging and genetics of acute and chronic cannabis effects<br>6. Grey matter, lateral ventricle volumes and executive functioning in cannabis users with first-episode psychosis<br>7. Comorbidity Between Cannabis Use and Attention-Deficit/Hyperactivity Disorder: Potential Moderators <br>8. Cannabis and Oral Bones: Deleterious Effects on Periodontitis and Dental Implants<br>9. Does cannabis use increase the risk of developing cancer in humans? <br>10. Cannabis and the use of amphetamine-like substances<br>11. Cannabinoid signaling in glioma cells and therapeutic implications<br>12. Cannabidiol as antioxidants<br>13. The anxiolytic effects of cannabidiol (CBD).<br>14. New Ethological and Morphological Perspectives for the Investigation of Panicolytic-Like Effects of Cannabidiol<br>15. Spice Use amongst United States Military Personnel<br>16. Cannabis use in fibromyalgia<br>17. Short instruments to screen for "problematic" cannabis use in general population surveys: a systematic review<br>18. Self-report of cannabis use<br>19. CANDIS Program: Modular Treatment of Cannabis Use Disorders<br>20. Engaging Cannabis Users in Treatment</p>